

Patents

X 10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Robert J. D'Amato)
 Serial No. **09/545,139**) Art Unit: 1614
 Filed: **April 7, 2000**) Examiner: Goldberg, J.
 For: **Methods and Compositions For The**)
Inhibition Of Angiogenesis With EM-138)

**PETITION TO WITHDRAW APPLICATION FROM ISSUE
 UNDER 37 C.F.R. §1.313(c)(2) FOR CONSIDERATION OF A REQUEST FOR
 CONTINUED EXAMINATION IN COMPLIANCE WITH 37 C.F.R. §1.114**

Assistant Commissioner for Patents
 Washington, D.C. 20231

FAX RECEIVED

FEB 25 2002


Sir:

PETITIONS OFFICE

The applicant hereby petitions the Office under 37 C.F.R. §1.313(c)(2) to withdraw the above-identified application from issue to permit consideration of a Request for Continued Examination in compliance with 37 C.F.R. § 1.114 for the purpose of consideration of newly identified references. The application is scheduled to issue March 12, 2002. A copy of the concurrently filed Request For Continued Examination is filed herewith. The U.S. Patent and Trademark Office is hereby authorized to deduct the fee for the Petition in the amount of \$130.00 as set forth in 37 C.F.R. § 1.17(h) as well as any additional fees that may be required under 37 C.F.R. § 1.16, or credit any overpayment, to Account No. 11-0855.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being sent by facsimile transmission to the Assistant Commissioner for Patents, to facsimile number 703-398-6916, on February 25, 2002.


 Jeffrey B. Arnold, Reg. No. 39,540

ATLLJB02#72487

02/26/2002 AKELLEY 00000028 110855 09545139
 01 FC:122 130.00 CH

Petition for Withdrawal 37 C.F.R. 1.313(c)(2)
U.S. Application Serial No. 09/545,139
2 of 2

The reason for the present Petition is the need for the Examiner's consideration of newly identified references that the Applicant has submitted herewith in a Supplemental Information Disclosure Statement.

A Request for Continued Examination, the requisite fee set forth in 37 C.F.R. § 1.17(e), and a submission including the Supplemental Information Disclosure Statement pursuant to 37 C.F.R. § 1.97 and 1.98 is filed concurrently with this petition.

In view of the foregoing, the Applicant requests that this Petition be granted, and that the references and applications be considered by the Examiner in the Continued Examination of this application. If the Petition is granted, a call to the undersigned attorney is respectfully requested.

Respectfully submitted,



By: Jeffrey B. Arnold

Reg. No. 39,540

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
Telephone: (404) 815-6500
Facsimile: (404) 815-6555
Attorney Docket No. 05213-0650 (43170-219681)



Attorneys at Law

Suite 2800 1100 Peachtree St.
Atlanta GA 30309-4530
404 815 6500 f 404 815 6555
www.KilpatrickStockton.com

FAX RECEIVED
February 25, 2002

direct dial 404 745 2461
direct fax 404 541 3113
JArnold@KilpatrickStockton.com

FEB 25 2002

FAX
PETITIONS OFFICE

RECIPIENT/ PHONE NO.	FAX NO.	COMPANY/ CITY, STATE, COUNTRY
Assistant Commissioner For Patents Attn: Examiner J. Goldberg, Art Unit 1614	703-308-6916	U.S. Patent and Trademark Office Box Patent Application Washington, DC 20231

TO: Jeffery B. Arnold 55
FROM: _____ PAGES (WITH COVER)
05213-0650 43170-219681
REFERENCE NO. CLIENT/MATTER NO.

PLEASE CALL 404 815 6497 IF YOU HAVE DIFFICULTY WITH THIS TRANSMISSION.

CONFIDENTIALITY NOTE:

The information contained in this fax message is being transmitted to and is intended for the use of the individual named above. If the reader of this message is not the intended recipient, you are hereby advised that any dissemination, distribution or copy of this fax is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and destroy this fax message.

COMMENTS

IMPORTANT

Re: Patent Application Serial No. 09/545,139 entitled,
Methods and Compositions For The Inhibition of Angiogenesis With EM-138

Per the attached Petition To Withdraw Application From Issue For Consideration of a Request For Continued Examination in Compliance With 37 CFR 1.114 (2 pgs.), Request For Continued Examination (RCE) (1 pg.), Information Disclosure Statement (3 pgs.), List of Cited Art References, PTO/SB/08A (2 pgs.), and art references (2 ea.).

TO BE COMPLETED BY KS OPERATIONS CENTER

TRANSMISSION RECEIPT DATE/TIME: _____

COMPLETED BY: _____ **JOB CODE** _____

703 6916

*** RX REPORT ***

RECEPTION OK

TX/RX NO	9910
CONNECTION TEL	
CONNECTION ID	
START TIME	02/25(MO)18:45
USAGE TIME	17'10"
PGS.	55
RESULT	OK